Prasinezumab for parkinson disease

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 4 registered trials.

Why this status

  1. 15 Sep 2025: Trial registered, NCT07174310
  2. 24 Nov 2025: Trial started, NCT07174310

The trials

NCT02157714: Multiple Ascending Dose Study of PRX002 in Patients With Parkinson's Disease

State
Completed
Phase
Phase 1
People
64 planned
Started
Jun 2014
Primary completion
Sep 2016
Arms
PRX002
Results
None posted
Papers
doi:10.1001/jamaneurol.2018.1487, doi:10.1002/mds.26878
  1. 6 Jun 2014: Trial registered
  2. 21 Oct 2016: Trial completed

NCT03100149: A Study to Evaluate the Efficacy of Prasinezumab (RO7046015/PRX002) in Participants With Early Parkinson's Disease

State
Under way
Phase
Phase 2
People
316 taking part
Started
27 Jun 2017
Primary completion
27 Nov 2019
Arms
Part 1: RO7046015 High Dose, Part 1: RO7046015 Low Dose, Part 2: RO7046015 High Dose, Part 2: RO7046015 Low Dose, Part 3: RO7046015 Low Dose
Results
Posted on the registry
Papers
doi:10.1001/jamaneurol.2018.1487, doi:10.1038/s41591-024-03270-6, doi:10.1038/s41598-022-15874-4, doi:10.1038/s41746-025-01572-8, doi:10.1056/nejmoa2202867, doi:10.1155/padi/8540084, doi:10.3389/fneur.2021.705407
  1. 4 Apr 2017: Trial registered
  2. 27 Jun 2017: Trial started
  3. 8 Feb 2021: Trial results posted

NCT04777331: A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson's Disease

State
Under way
Phase
Phase 2
People
586 taking part
Started
5 May 2021
Primary completion
11 Sep 2024
Arms
Prasinezumab
Results
Posted on the registry
Papers
doi:10.1016/s0140-6736(26)00865-2
  1. 2 Mar 2021: Trial registered
  2. 5 May 2021: Trial started
  3. 2 Dec 2025: Trial results posted

NCT07174310: A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease

State
Under way
Phase
Phase 3
People
900 planned
Started
24 Nov 2025
Primary completion
30 Jun 2029
Arms
Prasinezumab
Results
None posted
Papers
doi:10.1016/s0140-6736(26)00865-2
  1. 15 Sep 2025: Trial registered
  2. 24 Nov 2025: Trial started

How the status changed

  1. 16 Nov 2026: First set: Phase 3 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.